Cite
HARVARD Citation
Nakamura, R. et al. (2016). Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet. 3 (2), pp. e87-e98. [Online].